title: [Imatinib-induced pulmonary toxicity].
abstract: Antineoplasic agent-induced pulmonary toxicity is an important cause of respiratory failure. These novel antineoplastic agents include imatinib mesylate, a protein tyrosine kinase inhibitor that is encoded by the Bcr-Abl gen created by the Philadelphia chromosome abnormality in chronic myeloid leukemia. Pulmonary toxicity of imatinib is directly related to the dose used. The more severe pulmonary manifestations include pleural effusion by water retention and interstitial pneumonitis. We report the first case published in Mexico ofimatinib-induced pulmonary toxicity and its management in the intensive care unit of the Medica Sur Clinic Foundation.
authors.affiliation: Unidad de Terapia Intensiva, Fundación Clínica Médica Sur, México DF, México.
authors.forename: Raúd
authors.initials: R
authors.lastname: Carrillo-Esper
authors.forename: Neisser
authors.initials: N
authors.lastname: Morales-Victorino
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008171:Lung Diseases / Q000139:chemically induced*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate